Sonsire Fernández-Castillo

Author

Also Known As

Castillo, Sonsire Fernández, Fernandez, Sonsire, Fernández-Castillo, Sonsire, S. Castillo, S. Fernandez, S. Fernández, Sonsire Fernandez, Sonsire Fernandez-Castillo, Sonsire Fernández, Sonsire Fernández Castillo

Publications

731

Citations

H-Index

Concepts

All Affiliations

Finlay Institute Center of Molecular Immunology (Cuba)University of Havana Cuban Neuroscience Center State Key Laboratory of Biotherapy

About

Sonsire Fernández-Castillo is an author at Finlay Institute specializing in medicine, immunology, and vaccine development.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	378
2	Immunology	9	9	290
3	Microbiology	5	5	129
4	Autoimmune Disease	1	1	34
5	Autoimmunity	1	1	34

Sonsire Fernández-Castillo

Publications

559

Citations

H-Index

Page 1

	Year	Citations
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies Yury Valdés-Balbín, Darielys Santana-Mederos, Lauren Quintero, ACS Chemical Biology VaccinationVaccine DevelopmentVirus InfectionPreclinical StudiesVaccine Target	2021	88
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva, The Lancet Regional Health - Americas	2022	44
A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae Gemma Año, Amaia Esquisabel, Marta Pastor, Vaccine VaccinationMucosal VaccinationVaccine DevelopmentMicrobiologyInfection Control	2011	43
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, Meiby Rodríguez-González, Vaccine VaccinationVaccine SafetyOpen Label PhaseHeterologous SchemeVaccine Development	2022	38
Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice Lissete Rodriguez, Yanelys Tirado, Fátima Reyes, Vaccine InflammationPulmonary TuberculosisAutoimmune DiseaseImmunologyTuberculosis	2011	34
Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice Reinaldo Acevedo, Adriana Callicó, Judith del Campo, Methods InflammationIntranasal AdministrationMicrobial PathogensMedicinePathogenesis	2009	32
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva, ImmunodeficienciesImmunologyImmunodominancePharmacotherapyImmunotherapeutics	2021	31
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults María Eugenia Toledo-Romaní, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez, Med VaccinationVaccine SafetySoberana Plus VaccinesVaccine DevelopmentAnti-sars-cov-2 Heterologous Scheme	2022	30
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and <i>Neisseria meningitidis</i> outer membrane vesicles Darielys Santana-Mederos, Rocmira Pérez-Nicado, Yanet Climent-Ruíz, RSC Chemical Biology	2021	29
OMV-based vaccine formulations against Shiga toxin producing<i>Escherichia coli</i>strains are both protective in mice and immunogenic in calves Matías Fingermann, Lucía Ávila, Maria Belén De Marco, Human Vaccines & Immunotherapeutics VaccinationMucosal VaccinationOuter Membrane VesiclesOmv-based Vaccine FormulationsMicrobial Toxin	2018	24

Page 1